0
0
10/24/23 at 5:56pm
Organization
MarketWatch
42 words
0
Comments
By Josh Beckerman Moderna said the first participant has been dosed in a Phase 3 study of mRNA-1083, its combination vaccine candidate against influenza and...
You are the first to view
https://www.marketwatch.com/story/first-participant-dosed-in-phase-3-study-of-moderna-flu-covid-combination-vaccine-mrna-1083-70b34e41
Create an account
or login to join the discussion